Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

No-Squeeze 3D breast scan could transform cancer detection

NCT ID NCT07705100

Diagnosis Sponsor: University of Arizona Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests a new type of breast imaging called upright breast CT (UBCT) that creates a 3D picture without compressing the breast like a mammogram. It uses a low radiation dose similar to standard mammography. The goal is to see if this device can help doctors detect breast cancer more clearly. The study includes women aged 40 and older who are either getting routine screening or have been referred for diagnostic imaging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
upright, dedicated breast CT (UBCT) device
What this could lead to
If successful, this could provide a more comfortable and potentially more accurate breast imaging method for cancer screening and diagnosis.
What could go wrong
This is an early feasibility study with only 50 participants, so results may not generalize. The device is not yet FDA-approved, and its ability to detect cancer better than standard mammography is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For the screening cohort, the inclusion criteria are, women: * (1) who were 40 years of age or older (typical screening age range), and, * (2) who were asymptomatic, and, * (3) who underwent or scheduled to undergo a standard-of-care 2-view bilateral digital breast tomosynthesis screening exam. For the diagnostic cohort, the inclusion criteria are, women: * (1) who were 40 years of age or older, and, * (2) who underwent a standard-of-care 2-view bilateral digital breast tomosynthesis exam, and, * (3) who were assigned BI-RADS category 4 or 5 after diagnostic work-up and are scheduled for biopsy. Exclusion Criteria: * Males * Women less than 40 years old * pregnant or lactating women * women with physical limitations (e.g., kyphosis) that may prohibit UBCT exam * women who have received radiation treatments to the thorax * women who have participated in a prior breast clinical trial that gave additional radiation dose * women who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as tuberculosis, and severe scoliosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer detection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.